Suppressor tRNAs at the interface of genetic code expansion and medicine
- PMID: 38798701
- PMCID: PMC11116698
- DOI: 10.3389/fgene.2024.1420331
Suppressor tRNAs at the interface of genetic code expansion and medicine
Abstract
Suppressor transfer RNAs (sup-tRNAs) are receiving renewed attention for their promising therapeutic properties in treating genetic diseases caused by nonsense mutations. Traditionally, sup-tRNAs have been created by replacing the anticodon sequence of native tRNAs with a suppressor sequence. However, due to their complex interactome, considering other structural and functional tRNA features for design and engineering can yield more effective sup-tRNA therapies. For over 2 decades, the field of genetic code expansion (GCE) has created a wealth of knowledge, resources, and tools to engineer sup-tRNAs. In this Mini Review, we aim to shed light on how existing knowledge and strategies to develop sup-tRNAs for GCE can be adopted to accelerate the discovery of efficient and specific sup-tRNAs for medical treatment options. We highlight methods and milestones and discuss how these approaches may enlighten the research and development of tRNA medicines.
Keywords: RNA therapeutics; genetic code expansion; nonsense mutations; premature termination codons; synthetic biology; tRNA; translation.
Copyright © 2024 Awawdeh, Radecki and Vargas-Rodriguez.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures


Similar articles
-
Efficient suppression of premature termination codons with alanine by engineered chimeric pyrrolysine tRNAs.Nucleic Acids Res. 2024 Dec 11;52(22):14244-14259. doi: 10.1093/nar/gkae1048. Nucleic Acids Res. 2024. PMID: 39558163 Free PMC article.
-
Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies.Pharmacol Ther. 2025 Aug 22;274:108919. doi: 10.1016/j.pharmthera.2025.108919. Online ahead of print. Pharmacol Ther. 2025. PMID: 40850535 Review.
-
Engineered tRNAs suppress nonsense mutations in cells and in vivo.Nature. 2023 Jun;618(7966):842-848. doi: 10.1038/s41586-023-06133-1. Epub 2023 May 31. Nature. 2023. PMID: 37258671 Free PMC article.
-
Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations.Nat Commun. 2024 Apr 5;15(1):2957. doi: 10.1038/s41467-024-47258-9. Nat Commun. 2024. PMID: 38580646 Free PMC article.
-
Therapeutic promise of engineered nonsense suppressor tRNAs.Wiley Interdiscip Rev RNA. 2021 Jul;12(4):e1641. doi: 10.1002/wrna.1641. Epub 2021 Feb 10. Wiley Interdiscip Rev RNA. 2021. PMID: 33567469 Free PMC article. Review.
Cited by
-
Tuning tRNAs for improved translation.Front Genet. 2024 Jun 25;15:1436860. doi: 10.3389/fgene.2024.1436860. eCollection 2024. Front Genet. 2024. PMID: 38983271 Free PMC article. Review.
-
Efficient suppression of premature termination codons with alanine by engineered chimeric pyrrolysine tRNAs.Nucleic Acids Res. 2024 Dec 11;52(22):14244-14259. doi: 10.1093/nar/gkae1048. Nucleic Acids Res. 2024. PMID: 39558163 Free PMC article.
-
An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations.Nucleic Acids Res. 2025 Jun 20;53(12):gkaf532. doi: 10.1093/nar/gkaf532. Nucleic Acids Res. 2025. PMID: 40539513 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources